Candel Therapeutics, Inc. (CADL) stock
CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.40−0.41 (-7.06%)
Close on Nov 17, 2026Market cap $413.20MP/E –Yield –
Candel Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Candel Therapeutics's enterprise value was $500.25M on Nov 11, 2026, against $179.12M a year earlier. Over the last 5 years it ranged from -$33.02M to $793.30M, with a median of $149.27M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $500.25M | +120.0% |
| 2025 | Dec 31, 2025 | $227.42M | -17.6% |
| 2024 | Dec 31, 2024 | $276.10M | +1301.4% |
| 2023 | Dec 29, 2023 | $19.70M | – |
| 2022 | Dec 30, 2022 | -$25.73M | -119.0% |
| 2021 | Dec 31, 2021 | $135.55M | – |
See a number that looks wrong?